North America’s medical devices industry saw a flat growth in deal activity during March 2019, when compared with the last 12-month average, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

A total of 74 medical devices industry deals worth $789.6m were announced for the region in March 2019, against the 12-month average of 74 deals.

Of all the deal types, venture financing saw most activity in March 2019 with 47 transactions, representing a 63.5% share for the region.

In second place was M&A with 22 deals, followed by private equity deals with five transactions, respectively capturing a 29.7% and 6.8% share of the overall deal activity for the month.

In terms of value of deals, M&A was the leading category in North America’s medical devices industry with $507.48m, while venture financing and private equity deals totalled $279.63m and $2.5m, respectively.

North America medical devices industry deals in March 2019: Top deals

The top five medical devices deals accounted for 74.2% of the overall value during March 2019.

The combined value of the top five medical devices deals stood at $585.7m, against the overall value of $789.6m recorded for the month. The top announced medical devices deal tracked by GlobalData in March 2019 was Alcon Laboratories’ $285m acquisition of PowerVision.

In second place was the $220m acquisition of MyoScience by Pacira Pharmaceuticals and in third place was Berwind Private Equity, Fisk Ventures, Life Sciences Greenhouse of Central Pennsylvania, Roche Venture Fund and Vivo Capital’s $38.7m venture financing of Maculogix.

The $22m venture financing of Ossio by OCV Partners, Ortho Vision and Secocha Ventures and Ben Franklin Technology Partners of Northeastern Pennsylvania, Life Sciences Greenhouse of Central Pennsylvania, Originate Ventures and Oscor’s venture financing of Micro Interventional Devices for $20m held fourth and fifth positions, respectively.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.